Key insights
- 10X Genomics (TXG) stock reached a 52-week high, driven by strong performance, a William Blair upgrade to Outperform, and positive developments in AI-driven drug discovery and spatial biology collaborations. The company also achieved top-line beats and adjusted EBITDA breakeven. However, ARK Invest's significant share sale and concerns about overvaluation present counterbalancing factors. Stifel maintained a Buy rating with a raised price target, citing strong new product
10X Genomics Inc (TXG) stock has reached a 52-week high, hitting $26.07, with shares currently trading at $26.32. According to InvestingPro analysis, the stock appears overvalued at current levels compared to its Fair Value estimate, placing it among companies on the most overvalued list. This milestone marks a significant recovery and growth for the company, which has experienced a remarkable 236.09% increase over the past year. The stock’s impressive performance reflects strong investor confidence and positive market sentiment towards 10X Genomics’ innovative solutions in the genomics sector. The surge to this 52-week high underscores the company’s resilience and potential for future growth, as it continues to make strides in advancing genomic research and technology. Investors seeking deeper insights can access a comprehensive Pro Research Report on TXG, available for this and 1,400+ other US equities.
In other recent news, 10X Genomics has been upgraded by William Blair to an Outperform rating, highlighting the company’s pivotal role in AI-driven drug discovery. This upgrade comes on the heels of 10X Genomics achieving five consecutive top-line beats and reaching adjusted EBITDA breakeven, with single cell volumes experiencing double-digit growth for the fourth consecutive quarter. Additionally, Bioptimus has launched the Spatial Tissue Embedding Learning Atlas in collaboration with 10X Genomics and Broad Clinical Labs, aiming to profile up to 100,000 patient tissue specimens across multiple continents.
In contrast, 10X Genomics faced a setback as ARK Invest sold over 473,000 shares, signaling a shift in investment focus towards gene-editing platforms. This move by ARK Invest has raised concerns about potential reductions in holdings by other institutional investors. Meanwhile, Stifel has raised its price target for 10X Genomics to $25, maintaining a Buy rating due to strong adoption of the company’s new Flex Apex product.
However, investor concerns were also fueled by a sell-off in spatialomics stocks, including 10X Genomics, following a tweet from Microsoft’s CEO about the GigaTIME AI model, which could impact demand for spatial proteomics. Wolfe Research noted that this development might lead to a decline in demand if AI technology replaces clinical applications. Despite these mixed developments, 10X Genomics continues to be a focal point in the genomics and AI-driven drug discovery sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Before you click "buy," know exactly where to set your stop-loss. Our Vision AI literally "sees" your TXG chart and delivers a complete risk management plan—entry, stop-loss, and profit target—in under 60 seconds.Protect your downside. Validate every trade. Invest smarter.